Safety Study Providing 12 Months Follow-up From First Exposure to HP802-247 in Subjects With Venous Leg Ulcer
NCT ID: NCT01658618
Last Updated: 2014-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
440 participants
OBSERVATIONAL
2012-09-30
2015-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. to identify new adverse events,
2. to examine ongoing adverse events not resolved in subjects who participated in the 802-247-09-029 trial,
3. to record wound status, and
4. to determine if there are differences in Health Related Quality of Life (HRQoL) associated with the treatment assignment from the 802-247-09-029 Trial.
Investigational means that HP802-247 has not been approved by the U.S. Food and Drug Administration (FDA).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study Providing 12 Months of Safety Follow-Up From First Exposure to HP802-247
NCT01970657
Dose Finding Study of HP802-247 in Venous Leg Ulcers
NCT00852995
Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers
NCT01656889
Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2
NCT01737762
A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers
NCT02154087
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HP802-247
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject was randomized in 802-247-09-029 and received at least one application of a test article.
* Subject has ended their participation in 802-247-09-029 by virtue of completing the study, or by dropping out prior to completion.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Healthpoint
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Herbert B Slade, MD
Role: STUDY_CHAIR
Chief Medical Officer
Tommy Lee, MSHS
Role: STUDY_DIRECTOR
Associate Director Clinical Operations
Robert Kirsner, MD
Role: PRINCIPAL_INVESTIGATOR
Investigator
William Marston, MD
Role: PRINCIPAL_INVESTIGATOR
Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Glendale, Arizona, United States
Phoenix, Arizona, United States
Phoenix, Arizona, United States
Tucson, Arizona, United States
Tucson, Arizona, United States
Carlsbad, California, United States
Castro Valley, California, United States
Laguna Hills, California, United States
Long Beach, California, United States
Los Angeles, California, United States
San Diego, California, United States
San Francisco, California, United States
Stockton, California, United States
Sylmar, California, United States
Washington D.C., District of Columbia, United States
Gainesville, Florida, United States
Hialeah, Florida, United States
Miami, Florida, United States
South Miami, Florida, United States
Tamarac, Florida, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Jacksonville, Illinois, United States
North Chicago, Illinois, United States
Springfield, Illinois, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Cambridge, Massachusetts, United States
Las Vegas, Nevada, United States
Emerson, New Jersey, United States
New York, New York, United States
Chapel Hill, North Carolina, United States
Akron, Ohio, United States
Tulsa, Oklahoma, United States
Dunmore, Pennsylvania, United States
Wyomissing, Pennsylvania, United States
Dallas, Texas, United States
Fort Worth, Texas, United States
Fort Worth, Texas, United States
San Antonio, Texas, United States
St. George, Utah, United States
Roanoke, Virginia, United States
Tacoma, Washington, United States
Vancouver, British Columbia, Canada
Greater Sudbury, Ontario, Canada
Hamilton, Ontario, Canada
London, Ontario, Canada
Sherbrooke, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
802-247-09-030
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.